Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells

The majority of gastrointestinal stromal tumors (GISTs) are driven by oncogenic KIT signaling and can therefore be effectively treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate. However, most GISTs develop imatinib resistance through secondary KIT mutations. The type of resistance m...

Descripción completa

Detalles Bibliográficos
Autores principales: Rausch, Jessica L., Ali, Areej A., Lee, Donna M., Gebreyohannes, Yemarshet K., Mehalek, Keith R., Agha, Aya, Patil, Sneha S., Tolstov, Yanis, Wellens, Jasmien, Dhillon, Harbir S., Makielski, Kathleen R., Debiec-Rychter, Maria, Schöffski, Patrick, Wozniak, Agnieszka, Duensing, Anette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083865/
https://www.ncbi.nlm.nih.gov/pubmed/32198455
http://dx.doi.org/10.1038/s41598-020-62088-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083865/
https://www.ncbi.nlm.nih.gov/pubmed/32198455
http://dx.doi.org/10.1038/s41598-020-62088-7

Ejemplares similares